Microbiology and Immunology

You are here

Home > Publications > Publications

Publications

Found 362 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is W  [Clear All Filters]
2021
Zhang H, Hsu H-C, Kahne SC, Hara R, Zhan W, Jiang X, Burns-Huang K, Ouellette T, Imaeda T, Okamoto R et al..  2021.  Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome.. J Med Chem. 64(9):6262-6272.
Beites T, Jansen RS, Wang R, Jinich A, Rhee KY, Schnappinger D, Ehrt S.  2021.  Multiple acyl-CoA dehydrogenase deficiency kills Mycobacterium tuberculosis in vitro and during infection.. Nat Commun. 12(1):6593.
Gold B, Warrier T, Nathan C.  2021.  A Multistress Model for High Throughput Screening Against Nonreplicating Mycobacterium tuberculosis.. Methods Mol Biol. 2314:611-635.
Saito K, Mishra S, Warrier T, Cicchetti N, Mi J, Weber E, Jiang X, Roberts J, Gouzy A, Kaplan E et al..  2021.  Oxidative damage and delayed replication allow viable Mycobacterium tuberculosis to go undetected.. Sci Transl Med. 13(621):eabg2612.
Saito K, Mishra S, Warrier T, Cicchetti N, Mi J, Weber E, Jiang X, Roberts J, Gouzy A, Kaplan E et al..  2021.  Oxidative damage and delayed replication allow viable Mycobacterium tuberculosis to go undetected.. Sci Transl Med. 13(621):eabg2612.
Antanasijevic A, Sewall LM, Cottrell CA, Carnathan DG, Jimenez LE, Ngo JT, Silverman JB, Groschel B, Georgeson E, Bhiman J et al..  2021.  Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM.. Nat Commun. 12(1):4817.
Giardina SF, Valdambrini E, J Warren D, Barany F.  2021.  PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance.. Curr Cancer Drug Targets. 21(4):306-325.
Wang H, Xu M, Engelhart CA, Zhang X, Yan B, Pan M, Xu Y, Fan S, Liu R, Xu L et al..  2021.  Rediscovery of PF-3845 as a new chemical scaffold inhibiting phenylalanyl-tRNA synthetase in Mycobacterium tuberculosis.. J Biol Chem. 296:100257.
Wang R, Ehrt S.  2021.  Rv0954 Is a Member of the Mycobacterial Cell Division Complex.. Front Microbiol. 12:626461.
Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D et al..  2021.  Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.. ACS Omega. 6(3):2284-2311.
Calderón F, Fairlamb AH, Strange M, Williams P, Nathan CF.  2021.  Surmounting structural barriers to tackle endemic infectious diseases.. J Exp Med. 218(9)
Yang HS, Racine-Brzostek SE, Karbaschi M, Yee J, Dillard A, Steel PAD, Lee WT, McDonough KA, Qiu Y, Ketas TJ et al..  2021.  Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients.. Biosens Bioelectron. 178:113008.
Yang HS, Racine-Brzostek SE, Karbaschi M, Yee J, Dillard A, Steel PAD, Lee WT, McDonough KA, Qiu Y, Ketas TJ et al..  2021.  Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients.. Biosens Bioelectron. 178:113008.
Aldridge BB, Barros-Aguirre D, Barry CE, Bates RH, Berthel SJ, Boshoff HI, Chibale K, Chu X-J, Cooper CB, Dartois V et al..  2021.  The Tuberculosis Drug Accelerator at year 10: what have we learned? Nat Med. 27(8):1333-1337.
Aldridge BB, Barros-Aguirre D, Barry CE, Bates RH, Berthel SJ, Boshoff HI, Chibale K, Chu X-J, Cooper CB, Dartois V et al..  2021.  The Tuberculosis Drug Accelerator at year 10: what have we learned? Nat Med. 27(8):1333-1337.
2020
Weskamp G, Tüshaus J, Li D, Feederle R, Maretzky T, Swendemann S, Falck-Pedersen E, McIlwain DR, Mak TW, Salmon JE et al..  2020.  ADAM17 stabilizes its interacting partner inactive Rhomboid 2 (iRhom2) but not inactive Rhomboid 1 (iRhom1).. J Biol Chem. 295(13):4350-4358.
Wang H, Wang C, Peng G, Yu D, Cui X-G, Sun Y-H, Ma X.  2020.  Capping Protein Regulator and Myosin 1 Linker 3 Is Required for Tumor Metastasis.. Mol Cancer Res. 18(2):240-252.
Wang H, Wang C, Peng G, Yu D, Cui X-G, Sun Y-H, Ma X.  2020.  Capping Protein Regulator and Myosin 1 Linker 3 Is Required for Tumor Metastasis.. Mol Cancer Res. 18(2):240-252.
Zaveri A, Wang R, Botella L, Sharma R, Zhu L, Wallach JB, Song N, Jansen RS, Rhee KY, Ehrt S et al..  2020.  Depletion of the DarG antitoxin in Mycobacterium tuberculosis triggers the DNA-damage response and leads to cell death.. Mol Microbiol.
Zaveri A, Wang R, Botella L, Sharma R, Zhu L, Wallach JB, Song N, Jansen RS, Rhee KY, Ehrt S et al..  2020.  Depletion of the DarG antitoxin in Mycobacterium tuberculosis triggers the DNA-damage response and leads to cell death.. Mol Microbiol.
Moallemian R, Rehman AUr, Zhao N, Wang H, Chen H, Lin G, Ma X, Yu J.  2020.  Immunoproteasome inhibitor DPLG3 attenuates experimental colitis by restraining NF-κB activation.. Biochem Pharmacol. 177:113964.
Giardina SF, Werner DS, Pingle M, Feinberg PB, Foreman KW, Bergstrom DE, Arnold LD, Barany F.  2020.  Novel, Self-Assembling Dimeric Inhibitors of Human β Tryptase.. J Med Chem. 63(6):3004-3027.
Song M, Wang C, Wang H, Zhang T, Li J, Benezra R, Chouchane L, Sun Y-H, Cui X-G, Ma X.  2020.  Targeting ubiquitin protein ligase E3 component N-recognin 5 in cancer cells induces a CD8+ T cell mediated immune response.. Oncoimmunology. 9(1):1746148.
Song M, Wang C, Wang H, Zhang T, Li J, Benezra R, Chouchane L, Sun Y-H, Cui X-G, Ma X.  2020.  Targeting ubiquitin protein ligase E3 component N-recognin 5 in cancer cells induces a CD8+ T cell mediated immune response.. Oncoimmunology. 9(1):1746148.
Gengenbacher M, Zimmerman MD, Sarathy JP, Kaya F, Wang H, Mina M, Carter C, Hossen MAmir, Su H, Trujillo C et al..  2020.  Tissue Distribution of Doxycycline in Animal Models of Tuberculosis.. Antimicrob Agents Chemother. 64(5)